Anzeige
Mehr »
Dienstag, 24.03.2026 - Börsentäglich über 12.000 News
Drohnenkrieg eskaliert - und diese Aktie greift nach zwei Mega-Märkten
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A41557 | ISIN: US0231114044 | Ticker-Symbol: EH3
Stuttgart
24.03.26 | 19:17
12,100 Euro
-1,63 % -0,200
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
AMARIN CORPORATION PLC ADR Chart 1 Jahr
5-Tage-Chart
AMARIN CORPORATION PLC ADR 5-Tage-Chart
RealtimeGeldBriefZeit
12,10012,60019:35
12,10012,60018:57

Aktuelle News zur AMARIN Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiAmarin Corporation plc: Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline3
16.03.Amarin Corporation plc: New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College ...4
07.03.Here's Why I Wouldn't Touch Amarin With a 10-Foot Pole Given Its Patent and Competition Risks18
05.03.AMRN Stock Soars 37.7% in a Year: Here's What You Need to Know16
03.03.Forget Amarin: This Oft-Overlooked Pharma Powerhouse Is a Better Buy Now14
02.03.AMARIN CORP PLC - 10-K, Annual Report1
AMARIN Aktie jetzt für 0€ handeln
26.02.Amarin's Q4 Earnings Beat Estimates, Stock Down as Revenues Miss5
25.02.Amarin down as topline contracts in Q46
25.02.Amarin GAAP EPS of $0.00 beats by $0.01, revenue of $49.2M misses by $1.42M5
25.02.Amarin Corp Earnings Report: Q4 Overview2
25.02.AMARIN CORP PLC - 8-K, Current Report1
24.02.Amarin Q4 2025 Earnings Preview4
23.02.Amarin Corporation plc: This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease9
20.01.Supreme Court agrees to review 'skinny label' battle between Hikma, Amarin over generic Vascepa32
10.01.Amarin Corporation (AMRN) Announces Select Unaudited Financial Highlights16
09.01.AMRN Stock Up 17% as Preliminary Q4 Sales Beat Expectations7
09.01.Amarin positioniert VASCEPA im Umfeld neuer Triglycerid-Therapien4
09.01.Amarin highlights VASCEPA's role amid new triglyceride therapies1
09.01.Amarin Corporation plc: Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company's VASCEPA/VAZKEPA (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization273DUBLIN and BRIDGEWATER, N.J., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today commented on...
► Artikel lesen
08.01.Amarin expects full-year 2025 revenue in-line with estimates15
Weiter >>
45 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1